Agenus Inc.

What they do

Agenus develops antibody-based immunotherapies, primarily BOT (anti-CTLA-4) and BAL (anti-PD-1), for cancer and infectious disease. The company also holds an equity investment in MiNK Therapeutics and a majority stake in SaponiQx, a vaccine adjuvant business. Following a December 2024 realignment, it prioritizes BOT/BAL programs while pausing non-core activities. Manufacturing is supported through a strategic collaboration with Zydus Lifesciences, which includes the sale of its biologics facilities.

Revenue drivers

• Pre-commercial product revenue from access programs — Revenue from regulatory-authorized compassionate access programs, primarily in France, contributed $6.4 million in Q2 2026 as BOT/BAL expands to additional countries.
• Licensing and collaboration milestones — Potential milestone payments from collaborations with Incyte (up to $315M, though terminated), Merck (up to $85M), and others, though many programs have been terminated or discontinued.
• Zydus collaboration — Total consideration of $91.0 million from the sale of manufacturing facilities and a supply agreement, with first tranche of clinical supply expected in 2026.

Recent performance

Revenue for the quarter ended June 30, 2026 was $34.5 million, up sequentially from $33.7 million in Q1 2026 and $34.2 million in Q4 2025. The company reported a net loss of $3.1 million for the full year 2025, a significant improvement from a $232.3 million loss in 2024. Operating cash flow for 2025 was -$77.2 million, improving from -$158.3 million in 2024. As of June 30, 2026, cash and equivalents were $18.7 million, with a shareholder equity deficit of $199.1 million.

Strategy

Management has prioritized BOT/BAL for neoadjuvant (pre-surgery) treatment of high-risk Stage II and Stage III MSS colon cancer, advancing the planned Phase 3 trial 'ROBBIN'. The company discontinued financial support for the CCTG-sponsored BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer. A July 2026 private placement raised $85 million in upfront gross proceeds, with potential additional $255 million from milestone-aligned warrants, to fund ROBBIN and operations. The company continues to expand physician access through compassionate use programs and appointed an exclusive global access distribution partner.

Risks

• Going concern — The independent auditor included a going concern explanatory paragraph, and the company has a shareholder deficit of $199 million with limited cash.
• Dependence on BOT/BAL — The business is highly dependent on the success of botensilimab/balstilimab; any clinical or regulatory setback would materially harm the company.
• Need for additional capital — If the warrants are not exercised, funding may only last through Q3 2027, requiring additional financing that could cause dilution or restrictive terms.
• Partner program terminations — Incyte terminated the entire collaboration agreement (effective February 2026), and several partner programs (OX40, GITR, LAG-3, TIM-3, undisclosed) have been discontinued, reducing future milestone potential.

Outlook

Management expects to initiate the ROBBIN Phase 3 trial and dose the first patient in Q1 2027, with upfront private placement proceeds supporting operations through Q3 2027. Assuming full warrant exercise, funding could extend through year-end 2031. The company expects to publish longer-term follow-up from NEST and UNICORN studies in the second half of 2026, and continues to expand access programs across additional countries.